Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor–Tezacaftor–Ivacaftor—A Pilot Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020814 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Senthilkumar Sankararaman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Feces, Gastrointestinal Microbiome, Chloride Channel Agonists. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Rainbow Babies & Children's Hospital, Rainbow Babies & Children’s Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Prior studies in people with cystic fibrosis (CF) demonstrated a positive impact of ivacaftor on the stool microbiome. However, studies evaluating the impact of elexacaftor–tezacaftor–ivacaftor (ETI) on gut dysbiosis are limited. In this prospective, observational study, we evaluated the differences in stool microbiome in children (aged 2–17 years) with CF who were treated with ETI for at least two months and compared with children with CF who did not receive ETI. We also included healthy siblings as controls. There were no significant differences in the demographics between the groups. There were no significant differences in alpha diversity between the groups for both bacteriome and mycobiome. Alpha diversity showed a negative trend with the duration of ETI therapy for both bacteriome and mycobiome. Firmicutes and Proteobacteria were the most abundant phyla and core members across all samples, regardless of disease status or treatment. Ascomycota and Basidiomycota were the most abundant and core members across all samples, regardless of disease status or treatment. Alpha diversity showed a negative trend with the duration of ETI therapy for both bacteriome and mycobiome in children with CF treated with ETI. Future studies are needed to confirm or refute our preliminary findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology, Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.
- Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Center for Medical Mycology, Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
- Division of Pediatric Pulmonology, Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.
- Department of Genetics and Genomic Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
ORCID-Profile: Senthilkumar Sankararaman, Ruitao Liu, Xinyu Sun, Thomas J Sferra, Mitch Drumm
Förderung
- NIDDK NIH HHS
- Rainbow Babies & Children's Hospital
- Rainbow Babies & Children’s Foundation
Zitieren
APA
Sankararaman, S., Liu, R., Sun, X., Retuerto, M., Schindler, T., Roesch, E., Sferra, T. J., Drumm, M., Ghannoum, M., & Zhang, L. (2026). Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor–Tezacaftor–Ivacaftor—A Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020814
Vancouver
Sankararaman S, Liu R, Sun X, Retuerto M, Schindler T, Roesch E, et al. Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor–Tezacaftor–Ivacaftor—A Pilot Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020814
BibTeX
@article{Sankararaman2026,
author = {Sankararaman, Senthilkumar and Liu, Ruitao and Sun, Xinyu and Retuerto, Mauricio and Schindler, Terri and Roesch, Erica and Sferra, Thomas J and Drumm, Mitch and Ghannoum, Mahmoud and Zhang, Liangliang},
title = {Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor–Tezacaftor–Ivacaftor—A Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020814}
}
EUVIMED